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Under certain circumstances, secondary B cells can preempt an immune
response and inhibit the expression of the products ofprimary B cells having the
same specificity. This effect was illustrated by experiments (1) that made use of
a major intrastrain crossreactive idiotype characteristic ofthe anti-Ars antibodies
of strain A mice (CRIA)'. The idiotype is absent in the anti-Ars antibodies of
BALB/c mice (H-2"; Igha), but present in allotype-congenic GAL-20 mice (H-
2", Igh"; references 1, 2). After transfer of lymphocytes from Ars-immune
BALB/c mice to mildly irradiated (200 rad) nonimmune GAL-20 recipients, the
latter produced no CRIA+ antibodies after immunization with KLH-Ars. It was
shown (1) that the inhibition of CRIA expression was mediated by the B cells of
the donor and that T cells were ineffective. A possible synergistic effect ofsmall
amounts ofcontaminatingcarrier-specificTscells was ruledout by using different
carriers for the hapten in the donor and recipient mice. The inhibition was
shown to persist for at least 5 mo after an adoptive transfer. Similar experiments
were carried out (3) by using A/J mice as a source oflymphoid cells for adoptive
transfer. These donor mice were idiotypically suppressed for CRIA and then
immunized. Mildly irradiated A/J mice that received either enriched B or T cells
from such donors expressed little or no CRIA upon subsequent immunization
against the Ars hapten. On a numerical basis, B cells were somewhat more
suppressive than T cells.
Experiments of similar design indicated that this effect can be used to suppress
an allotype as well as an idiotype (4). Spleen cells from BALB/c mice immunized
with KLH-TNP were adoptively transferred into irradiated (200 rad) allotype-
congenic partners (C.B-17), which were then immunized to TNP. Through day
58 after the adoptive transfer, ?80% ofthe IgG antibody produced was ofdonor
allotype. By day 110, the allotype of the host dominated in most but not all
recipients . Other recipients that were given nonimmune BALB/c cells produced
antibodies almost entirely of the recipients' allotype. The participation ofT cells
in the suppression was not completely ruled out but appears improbable; i. e., it
seems unlikely that immunized BALB/c mice would produce Ts cells specific for
an unrelated allotype. An explanation consistentwith each set ofresults discussed
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above is that secondary B cells can dominate a response by virtue of their great
numerical superiority and greater east oftriggering as compared with the primary
B cells of the same specificity, present in the recipient animal .
The present experiments were designed to ascertain whether this effect can
be exploited to inhibit the synthesis of IgE antibodies of a given specificity. The
experiments trade use of the observation that immunization with antigen emul-
sified in CFA induces the synthesis of large amounts of antibodies that are almost
devoid of IgE. This permitted the adoptive transfer of non-IgE-producing
immune B cells into naive recipients, which were then tested for their capacity
to produce IgE antibodies of the same specificity . Related experiments were
carried out without adoptive transfer by immunizing individual mice successively
with antigens in CFA and alum; the latter adjuvant is permissive for IgE synthesis.
Materials and Methods
Mice.
￿
Female A/J mice were obtained from The Jackson Laboratory, (Bar Harbor,
ME). Within an experiment, the mice were age matched. The range of ages at the start
of an experiment was 6-12 wk.
Antigens and Adjuvants.
￿
KLH was obtained from Calbiochem-Behring Corp. (LaJolla,
CA); OVA was from Miles Laboratories Inc. (Naperville, IL); and BSA (fraction V) was
from Sigma Chemical Co. (St. Louis, MO). Ars derivatives of KLH, OVA, or BSA were
prepared by diazotization (5). TNP derivatives of KLH and BSA were prepared by
conjugating trinitrobenzene sulfonate to the protein at pH 8.0 in saline-borate buffer for
2 h at room temperature (6). The weight ratio of hapten to protein used for coupling was
1 :25. Alum was prepared from aluminum sulfate and sodium hydroxide according to the
method of Levine and Vaz (7). The alum was thoroughly mixed with antigen solution
shortly before use ; 4 mg of alum was present in each inoculum, and the volume injected
was 0.5 ml . CFA (Difco Laboratories Inc., Detroit, MI) was used as a 1 :1 emulsion with
the antigen solution or with saline; 0.2 ml ofthe emulsion was inoculated into each mouse.
All inoculations were given intraperitoneally. Bleedings were taken 6 d after the second
and third inoculations of antigen in alum. We found that IgE anti-Ars titers are at a
maximum 6 d after challenge.
Radioimmunoassays. Assays for total anti-Ars were carried out on microtiter plates
whose wells were coated with BSA-Ars, using a 1 nrg/mi solution of the conjugate (8, 9).
We used "'I-labeled, affinity-purified rabbit anti-mouse Fab as the developing reagent.
Assays for IgE anti-Ars were done in a similar manner, using 121'I-labeled affinity-purified
rabbit anti-mouse IgE for development (10). The anti-IgE was prepared against the IgEK
protein TIB-142 (American Type Culture Collection, Rockville, MD; donated by M .
Wabl), which has anti-TNP activity. Adsorptions of the anti-IgE were carried out as
described elsewhere (11). For affinity purification, the mAb SE1 .3 (anti-Ars, IgEtc; refer-
ence 12) was conjugated to Sepharose-4B; after passage through a column of this
adsorbent, anti-IgE was eluted with 3 M NaSCN.
To minimize errors owing to the presence in sera of non-IgE anti-Ars (which competes
with IgE for binding to the BSA-Ars on the microtiter plate), serum samples were
precipitated with ammonium sulfate, at 39% of saturation, before the assay for IgE anti-
Ars. This removes a large proportion of IgG anti-Ars while leaving 80-100% of the IgE
in solution (11). Despite the precipitation step, a few samples required moderate correc-
tions, up to 25%, because of the presence of residual non-IgE anti-Ars. The procedure
for making such corrections, which requires a prior determination of total anti-Ars, is
described in detail in reference 11 . Assays for total anti-TNP and IgE anti-TNP antibodies
were carried out by procedures analogous to those used for total and IgE anti-Ars. Wells
were coated with SSA-TNP (I mg/ml). All assays were carried out in duplicate. The data
in the tables are expressed as mean values for the group of trice tested ± SEM .
Standards used for the assays for total anti-Ars and IgE anti-Ars were anti-Ars antibodies2020
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affinity purified from hyperinunune A/J ascites (13) and the mAb SE20.2 (anti-Ars, IgEK;
reference 12), respectively. The standard used for total anti-TNP was a DEAE-cellulose-
purified fraction of ascitic fluids of KI,H-TNP-immune A/J mice. The anti-TNP content
was determined by the quantitative precipitin test. Precipitates were dissolved in 0.1 M
Na0H and absorbances at 280 and 400 urn were determined. The latter value was used
to correct for the content of antigen . The standard for IgE anti-TNP was mAb T I B-142,
affinity purified as described elsewhere (11).
Preparation of Enriched Splenic T and B Cells.
￿
Single-cell suspensions of spleen were
treated on ice for 5 min with a solution containing 0.155 M NH4C1, 0.01 M KHCO, and
0.001 M EDTA, pH 7.4, to lyse erythrocytes . To enrich for T cells, we used two cycles
of panning on anti-Ig antibody-coated plastic surfaces (14). In brief, leukocytes in RPMI
1640 medium, supplemented with 5% FCS, were placed on 100-mm Petri dishes (10"
cells/5 ml medium/dish) precoated with a mixture of affinity-purified rabbit anti-mouse
Fab antibodies (10 Ag/ml) and nonspecific rabbit IgG (90 Feg/ml). The cells were allowed
to stand for 40 min at 4°C, and after gentle agitation, for an additional 30 min (1st cycle).
The nonadherent cells were resuspended by swirling and were then removed. The plates
were washed twice with cold PBS containing 3% FCS, and the supernatant was added to
the pool of nonadherent cells. The nonadherent cells (6 x 107/5 ml medium/dish) were
subjected to a second cycle of panning in the same manner, on dishes precoated with 200
Leg/ml (rather than 10 Icg/ml) of affinity-purified rabbit anti-mouse Fab antibodies.
Recovery of the nonadherent cells (T cell fraction) was 25-30% of the original spleen cell
population; >80% of these cells were killed by monoclonal anti-Thy-1 .2 plus C.
To enrich for B cells, the adherent cells were recovered from the anti-Fab-coated
plates used for the first cycle of panning. The plates were washed three times with cold
PBS, 10 ml of PBS containing 3% FCS was added at room temperature, and adherent
cells were released by vigorous pipeting, using a 10-ml plastic pipet. This cell population
was then treated with anti-Thy-1 .2 and "Low-Tox" rabbit complement (Cedarlane Labo-
ratories, Hicksville, NY). Recovery of this enriched B cell populaton was ^-25% of the
original cell population, and >95% of the cells were viable. A second treatment of these
cells with anti-Thy-1 .2 plus C showed the absence of significant contamination by T cells.
Results
The major aim of this work was to determine whether IgE anti-Ars synthesis
is inhibited by the presence of B cells committed to the synthesis of non-IgE anti-
Ars. Our approach to this question made use of previous observations (15-18),
which indicated that antigens administered in CFA yield high titers of antibodies
containing little if any IgE. In general, alum is a much better adjuvant for the
induction of IgE antibodies (e. g., reference 18). Our first experiments were
carried out to test these premises and to establish conditions appropriate for
investigating the inhibition of IgE synthesis by non-IgE-producing B cells.
The data in Table 1, groups 1 and 2, indicate that alum is much more effective
than CFA as an adjuvant for the production of IgE anti-Ars antibodies . For
example, at day 48, when the titers of total anti-Ars were comparable in the two
groups, more than 20 times as much IgE anti-Ars was present in mice immunized
with KLH-Ars in alum.
In addition, the data for groups 3 and 4 (compared with group 1) indicate that
the prior administration of KLH-Ars in CFA greatly inhibited the production of
IgE anti-Ars (but not total anti-Ars), when the mice were subsequently challenged
with KLH-Ars in alum . The results for groups 1 and 5 demonstrate that similar
inhibition of IgE production was induced by prior administration, in CFA, of
unconjugated KLH ; i. e., the presence of hapten groups in the immunogen was
not required to cause inhibition of IgE anti-Ars production.TABLE I
Effects ofPreinoculation ofCFA, with or without Antigen, on Stimulation of IgE, anti-Ars by
KLH-Ars in Alum
HABA ET AL .
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Anti-Ars titers (ng/ntl)
Lu:h group contained seven puce. Results are mean values ± SEM . Inoculations were intraperitoneal, using 20 vg of antigen (with CFA) or 5
,ug (with alum) . The volume ratioof antigen solution (or saline) to CFA was 1 :1 and 0 .2 tul was inoculated . 4 tng of alum was used and the final
volume was 0. .5 in] .
In contrast, preinoculation of CFA alone (group 6) did not result in selective
inhibition of IgE anti-Ars formation . On day 27, the titer of IgE anti-Ars was
somewhat lower than that of group 1, but the ratios of IgE/total anti-Ars are
similar in the two groups . On day 48, this ratio is actually somewhat higher in
mice of group 6, which had received CFA ; this is due to a lower total anti-Ars
titer in group 6, since the IgE anti-Ars concentrations are similar .
Mice in group 7 received four inoculations of CFA without antigen before
challenge with KLH-Ar . This appears to result in considerable inhibition of total
anti-Ars titers obtained after challenge with KLH-Ars in alum, but in either no
effect (day 27) or an enhancement (day 48) of IgE anti-Ars antibody titers .
The experiments described in Table II served two purposes : to ascertain the
effect of preinoculation of a higher dose (100 vs . 20 )ug) of KLH-Ars or KLH in
CFA, and to test the effects of preinoculation, in CFA, of another pair of
antigens, OVA and OVA-Ars . In all cases, mice were subsequently challenged
three times, with KLH-Ars in alum, on days 0, 21, and 42 .
Resultsobtained for group 2 (Table II) confirmed the absenceofanysignificant
inhibitory effect of preinoculation ofCFA alone on the subsequent IgE anti-Ars
response to KLH-Ars in alum ; we saw a moderate decrease on day 27, but the
two groups were very similar on day 48 . The inhibitory effect of preinoculation
ofCFA on the total anti-Ars response (Table I) was confirmed by results obtained
for group 2 (Table I1) .
The data in Table II, groups 3 and 4, further demonstrate that preinoculation
of a high dose (100 Ag) of either KLH-Ars or KLH markedly inhibited the
subsequent IgE anti-Ars response to KLH-Ars administered in alum (cf., groups
l , 2, 3, and 4) .
Results for groups 5 and 6, however, indicate a marked difference between
the effects of preinoculation ofOVA and OVA-Ars. There was strong inhibition
Group Antigen Days ofinoculations
Day
Total
x 10-1
27
IgE
'fotal
x 10 -1
Day 48
IgE
Ratio of
IgE/total
anti-Ars x 10'
1 KI-H-Ars(Alum) 0, 21,42 240 ± 70 2,070 ± 640 3,380 ± 1,000 2,280 ± 330 6 .7
2 KLH-Ars(CFA) 0, 21, 42 1,980 ± 380 20 ± 10 4,340 ± 1,060 100 ± 50 0 .2
3 KI.H-Ars(CFA) -42,-21 10,970 ± 1,240 40 ± 40 - - -
KI.H-Ars(Alum) 0,21
4 KIJ1-Ars(CFA) -21 1,650 t 460 330 ± 120 7,750 ± 890 190 ± 120 0 .2
KI.H-Ars(Alum) 0, 21, 42
5 KI.H (CFA) -42,-21 240 ± 120 320 ± 130 1,800 ± 78 280+ 140 1 .5
KLH-Ars (Alum) 0, 21, 42
6 CFA (saline) -42,-21 110 ± 40 990 ± 410 810 ± 170 2,740 ± 870 33 .8
KLH-Ars (Alum) 0, 21, 42
7 CFA (saline) -84, -63, -42, -21 110 t 40 2,090 ± 810 390 ± 80 6,280 ± 1,6311 161
KLH-Ars (Alum) 0, 21, 422022
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TABLE II
Effect ofPreinoculations ofAntigens on the Total and IgF anti-Ars Response to KLH-Ars in Alum
Anti-Ars titers (ng/tnl)
Day -1 5
￿
Dav -I
￿
Day 27
￿
Dap 48
Each group contained 9 (groups 2, 5, 6) or 10 mien (groups l, 3, 4) . Fhe preinoculations specified mere given on daps -42 and -21 ;
inoculations of KLH-Ars in alum (5 mg) were given on din-, 0, 21, an,~ .12 . All inondations were intraperitoneal (see 'Fable I for volumes
ino(ulated) .
* Probability of a significant decrease in the IgE, anti-At :s titer as co npared with group 2 . Statistical analyses were carried out by the students
t test .
of the synthesis of IgE anti-Ars after preinoculation ofOVA-Ars in CFA, but we
saw little if any effect when unconjugated OVA was administered in CFA before
challenge with KLH-Ars in alum .
Adoptive Transfer of Spleen Cells or Enriched T or B cells.
￿
To explore further
the mechanism of the inhibition of IgE anti-Ars synthesis that was induced by
preinoculation of KLH, KLH-Ars, or OVA-Ars (but not OVA), adoptive transfer
experiments were carried out (Table II1) . Donor A/J mice were either not
immunized, immunized with CFA alone, or with antigen in CFA. 3 X 107 cells
were transferred (day -1) into normal adult A/J recipients, which were then
immunized intraperitoneally with 5 hg KLH-Ars in alum on days 0, 21, and 35 .
Control mice (groups 1-7) received no cells, cells from naive animals, or cells
from animals that had received CFA without antigen .
It is evident, first, that adoptive transfer of spleen cells, or enriched T or B
cells from mice immunized with CFA (groups 5-7), had little effect on the IgE
response at day 41 . This confirms the results obtained by preinoculation of CFA,
followed by KLH-Ars in alum (Tables I and II) . In contrast, marked selective
inhibition of IgE anti-Ars synthesis was noted after adoptive transfer of spleen
cells or B cells from mice immunized with KLH-Ars in CFA (groups 8-10 ; seep
values) . After adoptive transfer of enriched T cells (group 9), there was some
inhibition of total, as well as IgE anti-Ars synthesis, possibly reflecting the
presence of a greater concentration of "I's cells in this population, as compared
with unfractionated spleen cells .
Adoptive transfer of cells from mice treated with KLH (rather than KLH-Ars)
in CFA failed to confirm the selective inhibition of IgE anti-Ars noted (Tables 1
and 11) after preinoculation of KLH without adoptive transfer . There was little
if any inhibition of IgE anti-Ars synthesis (cf., groups 5-7 with groups 11-13) .
A point of major interest in Table III emerges from the effects of transferring
GIextp Preinoculations
Total
X 10-1
IgE
1- otal
X 10 -s
IgE
Total
X 10-s
Igi :
7 otal
X 10 -1
IgE p *
Ratio of
IgE/total
anti-Ars X 10°
I None - - -- - 690 1,830 6,350 3,370 - 5 .3
- 80 +290 - 860 t 600
2 CFA 170 790 1,700 3,270 - 19 .2
± 511 ± 260 ± 460 ± 980
3 1110 pg KLH-Ars 1.890 100 4,810 80 7,0011 180 0,260 13(1 0.008 0 .2
in CFA ± 210 - 20 ± 540 - 30 ± 1,270 - 30 - 860 t 30
4 100 jug KLH in - - -- - 460 480 2,470 160 0.009 0 .6
CFA 160 - 170 - 470 +40
5 200pgOVA-Ars 760 50 1.330 20 1,7711 230 1,730 370 0.016 2 .1
in CFA ± 1411 - 2 ± 290 ± 10 ± 540 ± 80 - 220 ± 110
6 200 pg OVA in - - -- - 90 1,180 3,630 2,930 >0 .2 8 .1
CFA ± 30 + 510 - 860 ± 730HABA ET AL .
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TABLE III
Total and IgE Anti-Ars Responses to KLH-Ars in Alum After Adoptive Transfers
Anti-Ars titers (ng/ml)
Donors were immunized on days -49 and -28 with 100,ug ofthe protein antigen in CFA, or with CFA emulsified with saline. 3 X 107 cells
were transferred intravenously into naive recipients on day -1 . Recipients were immunized intraperitoneally with 5 lag KLH-Ars in alum on
days 0, 21, and 35. Groups 8 and 9 contained six mice ; other groups, seven mice.
* For a decrease in the IgE anti-Ars titer as compared with the group number specified in parentheses .
cells from donors immunized with OVA-Ars or OVA. OVA-Ars-immune spleen
cells or enriched B cells caused a marked selective inhibition of IgE anti-Ars
synthesis (groups 14 and 16), whereas we saw no such effect after transfer of
OVA-Ars-immune T cells (group 15) . None of the transferred cell populations
from donors immunized with unconjugated OVA were significantly inhibitory
with respect to IgE anti-Ars production (see p values, groups 17-19) .
We next examined the dose response of mice receiving varying numbers of
cells (on day -1) from donors that had been immunized with OVA-Ars in CFA
before the adoptive transfer . Recipients were challenged with KLH-Ars in alum
on days 0, 21, and 35 . The data for groups 8 and 9, Table IV, confirm the
Group
Immunization
ofdonors
Cells trans-
£erred
Day
Total
X 10-1
15
g IE
Day
Total
X 10 -1
27
I
g
E Total
X 10-1 IgE
Day 41
A *
Ratio of
IgE/total
anti-Ars X 10"
1 - None 40 140 610 2,000 4,210 1,880 - 4.5
±7 +40 ± 50 ±350 ± 520 ± 340
2 Nonimmune Spleen 40 120 530 1,600 4,950 3,720 - 7.5
±5 t 20 ± 110 ±300 ± 1,000 ± 1,530
2 Nonimmune T 40 60 670 1,270 5,390 2,230 - 4.1
±6 ± 20 =250 ±300 ± 900 ± 770
4 Nonimmune B 50 240 850 1,830 4,450 2,790 - 6.3
±6 1 100 ± 90 ±630 ± 600 ± 960
5 CFA Spleen 20 40 360 690 2,310 2,200 - 9.5
± 3' ± 20 ± 130 ± 190 ± 540 ± 610
6 CFA T 30 140 290 750 2,780 1,820 - 6.5
± 8 ± 90 ± 70 ± 120 ±630 ± 500
7 CFA B 20 110 400 2,110 2,970 1,660 - 5.6
± 4 t 60 ± 100 ±550 ±610 ±350
8 KLH-Ars (CFA) Spleen 1,990 0 1,280 200 2,670 220 0.016 0.8
± 140 ±490 +50 ±230 ±60 (vs. 5)
9 KLH-Ars (CFA) T 280 0 200 60 840 340 0.033 4.0
±20 t 40 ± 20 f 120 ± 180 (vs, 6)
10 KLH-Ars (CFA) B 1,180 160 830 470 2,610 460 0.014 1.8
± 140 ± 70 ± 120 t 180 ±470 ± 50 (vs . 7)
11 KLH (CFA) Spleen 20 240 320 1,010 2,140 1,640 >0 .2 7.7
± 2 ± 120 ± 150 3360 ±480 ±420 (vs. 5)
12 KLH (CFA) T 60 120 400 570 2,250 1,130 >0 .2 5.0
± 10 ± 60 ± 110 ±230 ±490 ±470 (vs . 6)
13 KLH (CFA) B 10 30 240 1,220 1,690 3,430 >0 .2 20 .3
t 1 ± 20 ± 30 ±310 ±270 1 1,280 (vs . 7)
14 OVA-Ars (CFA) Spleen 450 90 670 180 1,940 450 0.026 2.3
±60 ±40 ±90 ± 60 ± 350 ± 100 (vs. 5)
15 OVA-Ars (CFA) T 60 260 280 1,220 1,920 1,710 >0 .2 8.9
± 10 ±90 ±70 t 420 ±410 ±550 (vs. 6)
16 OVA-Ars (CFA) B 450 60 810 270 2,050 270 0,009 1 .3
± 10 ±30 1 170 ± 110 ± 400 ± 130 (vs.7)
17 OVA (CFA) Spleen 60 180 530 1,240 3,200 1,410 >0 .2 4.4
± 10 ±40 ±90 ± 370 ±610 ±580 (vs. 5)
18 OVA(CFA) T 30 140 420 2,840 2,210 2,030 >0 .2 9.2
±4 ± 50 ±80 ± 450 ± 360 ±510 (vs. 6)
19 OVA (CFA) B 40 210 480 2,080 2,870 1,500 >0 .2 5.2
± 10 ±70 ± 110 ± 360 ± 620 ±370 (vs. 7)2024
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TABLE IV
Effect of Transfer of Varying Numbers of OVA-Ars-primed Cells on the IgE Anti-Ars Response
Discussion
Anti-Ar titers (ng/ml)
Donors of cells had been primed with 200 ug OVA-Ars in CFA, inoculated intraperitoneally on days -56 and -35 . Cells were transferred
on day -1 . Recipients were inoculated intraperitoneally with 5 pg KLH-Ars in alum on days 0, 21, and 35 .
* For a significantdecrease in the IgE anti-Ars titer as compared with group l .
absence ofany significant inhibitory effect of transferred T cells on subsequent
IgE anti-Ars production . In contrast, 3 X 107 or 1 X 10 7 unfractionated spleen
cells caused a highly significant decrease in IgE anti-Ars production, whereas 3
X 10' spleen cells had considerably less effect (groups 1-4) . Very similar results
were obtained after transfer of enriched B cells ; 1 . e., marked inhibition of IgE
anti-Ars after transfer of 3 X 107 or 1 X 107 cells, and a lesser effect of 3 X 106
cells (groups 1, 5-7) . These results indicate that the inhibition of IgE anti-Ars
synthesis by B cells is not attributable to contamination with T cells .
The specificity of inhibition of IgE synthesis after adoptive transfer of OVA-
Ars-primed spleen cells is shown by the data in Table V . Again, marked inhibition
of IgE anti-Ars synthesis is seen in the mice that received spleen cells from donors
immunized with OVA-Ars in CFA (group 2), but not in mice that received
OVA/CFA-primed spleen cells (group 3) . When the recipients of OVA-Ars-
primed cells were immunized with KLH-TNP, we saw no significant decrease in
IgE anti-TNP (cf., groups 4 and 5) .
The results reported here bear on the following subjects : (a) inhibition of
antibodies of a given isotype (IgE) mediated by secondary B cells producing
antibodies of the same specificity but ofa different isotype ; (b) other effects on
IgE synthesis of preinoculations of CFA, or CFA plus antigen, before challenge
with antigen in alum . The experiments were based on the previous observations
(15-18) that minimal or undetectable amounts of IgE antibodies are produced
when certain antigens are administered to mice (or rats) as an emulsion in CFA,
Group
Cells trans-
ferred
Number of
cells
Day
Total
x 10 -
15
g 1E
Day
Total
x 10- s
27
IgE Total
x 10-s IgE
Day 41
p*
Ratio of
IgE/total anti-
Ars x 10'
1 None - 15 140 890 2,800 2,950 2,640 - 9.0
± 3 t8 ± 170 ±400 ±350 ± 790
2 Spleen 3 x 107 510 250 1,470 260 1,370 360 0.004 2.6
± 100 ± 70 ±230 t 70 ± 110 ± 110
3 Spleen 1 x 107 260 140 980 370 990 260 0.002 2.6
± 50 t 50 ± 180 ± 80 ± 140 t60
4 Spleen 3 x 106 160 310 710 1,050 1,540 920 0.013 6.0
± 20 ± 100 ± 160 ±430 ± 290 ± 350
5 B cells 3 x 107 880 390 1,940 320 1,590 250 0.002 1 .6
t 60 ± 70 ±210 t 40 ±230 ± 40
6 B cells I x 107 420 470 1,210 340 1,100 320 0.003 2.9
± 60 ± 80 ± 120 ± 110 ± 150 ±70
7 B cells 3 x 10 6 310 110 820 550 1,000 610 0.008 6.1
± 60 ± 20 ± 100 ±380 ±180 ± 420
8 T cells 3 x 107 80 490 420 1,780 2,690 2,360 >0 .2 8.8
± 20 t 90 t 30 1320 ±320 ± 560
9 T cells I x 107 20 510 780 4,700 3,580 3,330 >0 .2 9.3
± 5 1 230 ± 150 ±670 ±390 ± 330HABA ET AL .
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TABLE V
Specificity ofInhibition ofIgF anti-Ars Synthesis Caused by Adoptive Transfer of
OVA-Ars-primed Cells
3 x 107 spleen cells were transferred on day -I from mice inununized with 200 pg of the antigen specified in column 2, in CFA, on days
-51 and -30 . Recipients were inununized with 5 pg KLH-Ars (groups 1-3) or 2 pg KLH-TNP (groups 4-6) in alum on days 0, 21 and 35 .
Fach group consisted of six mice.
* Anti-Ars, groups 1-3 ; anti-TNP, groups 4-6 .
although high concentrations of non-IgE antibodies are induced . Our experi-
ments (Tables I and II) confirmed these reports . This permitted adoptive transfer
experiments to identify the cell type(s) responsible for the inhibition of IgE
production . Because several parameters need to be discussed we will consider
the data in terms of the antigen used for preinoculation (when individual mice
were immunized successively with two substances), or for immunizing donors
before adoptive transfer .
Preinoculations of OVA or OVA-Ars in CFA. OVA and OVA-Ars will be
considered first because they appear to provide the most cogent data supporting
an inhibitory effect of antigen-specific non-IgE B cells on the synthesis of IgE
antibodies of the same specificity . When mice were inoculated with OVA-Ars in
CFA before KLH-Ars in alum, there was marked inhibition of the IgE anti-Ars
response as compared with mice that received only CFA before KLH-Ars (Table
11) . There was no significant inhibition of the total anti-Ars response . Preinocu-
lation of OVA, rather than OVA-Ars in CFA, did not inhibit IgE (or total) anti-
Ars synthesis upon subsequent challenge with KLH-Ars in alum . Adoptive
transfer experiments (Table III) indicated that the inhibitory effect on IgE anti-
Ars synthesis of preinoculation of OVA-Ars in CFA is mediated by B cells .
Unfractionated spleen cells or enriched B cells were inhibitory in recipient mice,
whereas the same number (3 X 107 ) of enrichedT cells was not . Cells transferred
from OVA/CFA-immune mice had no significant effect on IgE anti-Ars produc-
tion . The experiments using OVA-Ars followed by KLH-Ars seem particularly
informative, since the change of carrier protein eliminates effects that might be
attributable to carrier-specific suppressor cells .
Further evidence that the inhibitory effect on IgE antibody synthesis, after
adoptive transfer, is mediated by B cells are the data on dose response . Whereas
10 7 enriched B cells from OVA-Ars/CFA-immune mice caused significant
inhibition, 3 X 107 enriched T cells were noninhibitory . This appears to rule out
contamination by T cells as an explanation for the B cell effect . The specificity
of the phenomenon was indicated by the failure of transferred Ars-immune
Group Cells transferred
Inununo-
gen
Day 15
Antibody
Day
titers (ng/ml)*
27 Day 41
Total X IgF: Total x
IgE Total x 10' IgE 10-3
1 None KLH-Ars 20 ± 6 80 ± 10 920 ± 20 2,160 ± 610 1,860 ± 410 2,460 ± 470
2 OVA-Ars inunune KLH-Ars 1,270 ± 70 200 ± 60 2,230 t 50 250 ± 40 2,830 ± 550 220 ± 30
3 OVA inunune KI-H-Ars 20 ± 6 100 ± 10 760 ± 70 1,490 ± 300 1,740 ± 500 1,910 ± 200
4 None KLH=fNP 70 ± 10 1,150 ± 260 220 ± 30 2,460 ± 330 1,500 ± 280 2,650 ± 700
5 OVA-Ars inunune KLH-'1-NP 60 ± 10 1,220 ± 490 160 ± 20 2,550 ± 1,240 1,520 t 300 2,670 ± 640
6 OVA inunune KI.H-TNP 70 ± 20 1,920 ± 470 180 ± 40 2,910 ± 920 1,340 t 500 3,550 f 1,3802026
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spleen cells to affect anti-TNP IgE synthesis. Possible mechanisms for the
inhibition by B cells are discussed below.
Preinoculation ofKLH-Ars/CFA.
￿
These data are consistent with an inhibitory
effect of Ars-specific, non-IgE B cells on IgE anti-Ars synthesis; they also bear
on the effect of T cells. Preinoculation of KLH-Ars/CFA caused a highly
significant decrease in IgE anti-Ars synthesis upon challenge with KLH-Ars in
alum (Table II). In contrast to preinoculation ofOVA-Ars, this inhibitory effect
was noted after adoptive transfer ofenriched T cells, as well as B cells or spleen
cells (Table III). This suggests a possible inhibitory role for carrier-specific (19-
22) or hapten-specific (23) Ts cells. This possibility is supported by the moderate
decrease in total anti-Ars (p = 0.024), as well as IgE anti-Ars synthesis (p =
0.033) after adoptive transfer of KLH-Ars-immune T cells (Table 111, group 9
vs. group 6).
Preinoculation of KLH/CFA.
￿
The effect of preinoculation of KLH in CFA
before challenge with KLH-Ars in alum is consistent with a carrier-specific T
cell effect. There was a highly significant decrease in IgE anti-Ars synthesis
(Table II, cf., groups 2 and 4). Since hapten was not conjugated to the antigen
used for preinoculation, it is difficult. to invoke a B cell effect. In this case,
adoptive transfer experiments were not consistent with the results ofthe prein-
oculations because the transfer of KLH/CFA-immune spleen, T or B cells had
little effect on the subsequent response to KLH-Ar in alum. It is not obvious
why the adoptive transfer experiments were negative, whereas preinoculation of
KLH within an individual mouse was inhibitory. A possible explanation is that
the effect of Tcells is simply diminished in this case by the adoptive transfer, as
compared with their effect in the intact mouse.
Preinoculation ofCFA.
￿
Inoculations of CFA alone, twice or four times, before
challenge with KLH-Ars in alum had no inhibitory effect on IgE anti-Ars titers
(Table I). There was, however, a definite inhibitory effect on total anti-Ars titers,
particularly after four preinoculations of CFA; i. e., four inoculations of CFA
increased the ratio of IgE/total anti-Ars . The absence of an effect of CFA
injection on IgE anti-Ars titers is supported by the results of adoptive transfers
of splenic T or B cells (Table III). The effect on total anti-Ars titers, after the
adoptive transfers, was also not significant (p > 0.2 in each case; p values for
total anti-Ars not shown in the Table). Thus, our data showed no significant
effect on IgE production of preinoculations with CFA without antigen. This
appears to contrast with some (but not all) ofthe data in the literature. However,
the regimen of inoculations and the strain or species used have varied consider-
ably. For example, Tung etal. (24) found that irradiated CAF, mice that received
50 x 10' spleen cells from syngeneic donors that had been primed with a DNP-
conjugated extract of ascaris, produced high titers of IgE anti-DNP antibodies
after immunization with the same antigen. Pretreatment of the recipients with
CFA virtuallyeliminated the IgE response. They also showed that CFA treatment
of low or intermediate responder mice (B6 or AKR, respectively) induced a
serum factor that inhibited the IgE response in lightly irradiated syngeneic
recipients. This effect was not seen in two high responder strains: BALB/c and
(SJLX BALB/c)F,.
In other studies it was shown that the serum or ascites of CFA-treated miceHABA ET AL.
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contain factors that can enhance or suppress IgE responses (25). IgE suppressive
factor has also been identified in supernatants of cultured lymphoid cells taken
from CFA-primed rats (26) or from rats infected with Nippostrongylus brasiliensis
(27). The latter treatment, however, resulted in the production of IgE-potentiat-
ing as well as IgE-suppressive factors (28).
A strong and selective inhibitory effect ofpreinoculation of CFA on IgE anti-
OVA production was noted by Smith and Butchko (29) in both high- or
moderate-responder mice. The difference in our results may be attributable to
differences in timing of administration ofCFA and antigen, which was shown to
be a critical factor in one system investigated (30).
Possible Mechanisms ofInhibition ofIgE . Anti-Ars Production by Non-IgE anti-Ars-
specific B cells. This is the major question addressed by our experiments. We
have included a discussion of IgE suppression by T cells because some of our
data are indicative of such an effect. Similar observations of inhibition by
secondary B cells have been made in other systems, using idiotyppc or allotypic
markers. These experiments are described in the Introduction. One interpreta-
tion of such results (1, 3, 4) is that secondary B cells exercise their inhibitory
effect through a mechanism ofclonal dominance over primary B cells based on
their large numerical superiority over the primary cells that differ with respect
to idiotype or allotype; as a consequence, the secondary B cells should be far
more effective in competing for antigen. Preferential triggering of secondary
cells may also be reinforced by a higher density of surface la molecules (31), as
well as a greater average avidity for the antigen (32, 33). Recent results of
Takemori and Rajewsky (34) suggest, however, that B cells may also play a more
active role in suppression; in their system, adoptively transferred, unprimed,
idiotypically suppressed B cells prevented the expression of the idiotype by
normal B cells. The mechanism of this effect is not known. The possibility must
be considered that such a suppressive effect could also be operative at the level
of isotype. The coexistence of IgG with small amounts of IgE antibodies in
normally immunized animals implies that once the process of inducing IgE is
initiated, the clonal dominance effect no longer can suppress IgE formation.
Antigen-specific suppression mediated by B cells is well documented. Possible
explanations have included inhibition by secreted antibodies via blockade of
epitopes of the antigen, or triggering of an antiidiotypic (antibody or T cells)
response leading to antigen-specific suppression (35). Other investigators have
observed the secretion ofsolublesuppressive factors by Bcellsexposed to antigen-
antibody complexes (36) or to heat-aggregated Ig (37). These factors suppress
polyclonal B cell responses, apparently by a nonspecific mechanism. The studies
of Masuda and collaborators (38, 39) indicate that the factor is secreted by FcR+
B cells and that neither T cells nor macrophages are required. None of these
observations appears to bear directly on the present results, in which we saw
isotype-specific inhibition by secondary B cells.
If our interpretation of the data is correct, i. e., that inhibition is attributable
to clonal dominance ofsecondary B cells, it might be possible to effect long-term
inhibition ofan IgE response through a manipulation that temporarily suppresses
IgE synthesis, while at the same time stimulating non-IgE B cells of the same
specificity.2028
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Summary
We found that the synthesis of IgE anti-Ars antibodies is strongly inhibited by
the presence of secondary non-IgE-producing cells that are specific for the Ars
hapten. Such B cells can be induced by inoculation ofa protein-Ars conjugate in
CFA. The effect is seen after inoculation of OVA-Ars in CFA followed by KLH-
Ars in alum, or, more convincingly, after adoptive transfer of B cells induced by
antigen in CFA. Dose-response data indicated that inhibition can be effected by
B cells containing noninhibitory numbers of contaminating T cells. Possible
synergistic effects of carrier-specific regulatory T cells were ruled out by using a
different protein carrier for immunization of donor and recipient mice. The
effect was shown to be specific for the hapten used for immunization of donor
mice.
Receivedfor publication 19 May 1986 and in revised form 14 August 1986.
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